NanoString Technologies, Inc. (NSTG) |
| 0.1053 -0.063 (-37.43%) 06-17 16:00 |
| Open: | 0.128 |
| High: | 0.13999 |
| Low: | 0.1025 |
| Volume: | 21,428,464 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.16 |
| Resistance 1: | 0.14 |
| Pivot price: | 0.09 |
| Support 1: | 0.09 |
| Support 2: | 0.05 |
| 52w High: | 0.13999 |
| 52w Low: | 0.1025 |
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
| EPS | -148490000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 50.645 |
| Profit Margin (%) | -102.44 |
| Operating Margin (%) | -75.83 |
| Return on Assets (ttm) | -30.9 |
| Return on Equity (ttm) | -1.0 |
Mon, 05 Feb 2024
Why Is NanoString Technologies (NSTG) Stock Down 59% Today? - InvestorPlace
Fri, 17 Nov 2023
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - PR Newswire
Mon, 06 Nov 2023
NanoString Technologies Inc (NSTG) Reports Q3 2023 Earnings: Revenue Grows by 63% Year on Year - Yahoo Finance
Tue, 03 Oct 2023
A*STAR’s Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics - Business Wire
Wed, 03 May 2023
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 13 Dec 2022
NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022 - BioSpace
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |